One such drug, tirzepatide (ZepboundTM), which targets both GLP-1R and and the GIP receptor (GIPR), was found to elicit a robust 20.9% and 25.3% weight loss in humans with obesity over 72- (10) and 88-week periods (11), and was recently approved by the FDA for weight management. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.